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BACKGROUND: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an
aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of
PODXL expression in colorectal cancer (CRC).
METHODS: Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a
prospective, population-based cohort study. Kaplan–Meier analysis and Cox proportional hazards modelling were used to assess the
impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS).
RESULTS: High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS
(hazard ratio (HR)¼1.98; 95% confidence interval (CI) 1.38–2.84, Po0.001) and 5-year OS (HR¼1.85; 95% CI 1.29–2.64,
P¼0.001); the latter remaining significant in multivariate analysis (HR¼1.52; 95% CI 1.03–2.25, P¼0.036). In addition, in curatively
resected stage III (T1–4, N1–2, M0) patients (n¼122) with tumours with high PODXL expression, a significant benefit from
adjuvant chemotherapy was demonstrated (pinteraction ¼0.004 for CSS and 0.015 for 5-year OS in multivariate analysis).
CONCLUSION:Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC. Our results also suggest that PODXL
may be a useful marker to stratify patients for adjuvant chemotherapy.
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Colorectal cancer (CRC) is one of the most common types of
human cancer worldwide with B1 million new cases detected
every year (Parkin et al, 2005). Early detection, adequate surgical
excision and optimal use of adjuvant treatment are of critical
importance for the clinical outcome. Currently, tumour stage at
diagnosis is the most important prognostic factor in CRC.
Adjuvant treatment is recommended for patients with stage III
and high-risk stage II disease (e.g. T4, tumour perforation,
insufficient lymph node staging). Many efforts have been made
to find molecular markers to identify high-risk disease and to
select patients for adjuvant treatment, but so far, none of them
have proven good enough for use in clinical routine.
Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane
protein belonging to the CD34 family. Podocalyxin-like 1 inhibits
cell–cell interaction through charge-repulsive effects and has
classically been ascribed to haematopoetic progenitor cells
(Doyonnas et al, 2005), vascular endothelial cells (Horvat et al,
1986) and in the renal glomerular podocytes where it has a vital
part in maintaining filtration pathways (Doyonnas et al, 2001). In
recent years, overexpression of PODXL has been found in several
different forms of cancer including breast and prostate cancer,
malignant brain tumours, testicular, hepatocellular and renal cell
carcinoma (Gregoire et al, 1995; Schopperle et al, 2003; Chen et al,
2004; Somasiri et al, 2004; Casey et al, 2006; Hayatsu et al, 2008;
Koch et al, 2008; Hsu et al, 2010; Cheung et al, 2011). In breast
cancer and renal cell carcinoma, high expression of PODXL has
been demonstrated to be an independent predictor of poor
prognosis (Somasiri et al, 2004; Hsu et al, 2010). The mechanisms
behind these observations are not fully understood, but PODXL
has been shown to interact with other proteins such as ezrin, an
established mediator of metastasis, in prostate cancer cells (Casey
et al, 2006) and to induce actin recruitment and microvillus
formation in breast cancer cells (Nielsen et al, 2007). In addition, a
recent study demonstrated that PODXL is a target of the tumour
suppressive miRNA-199a and that cellular depletion of PODXL in
testicular tumours results in suppression of cancer invasion
(Cheung et al, 2011). Podocalyxin-like 1 also has an important
role in epithelial-mesenchymal transition (EMT), a process
involved in initiating the invasive and metastatic behaviour of
epithelial cancer cells, by regulating and interacting with collagen
type 1, E-cadherin and vimentin (Meng et al, 2011).
Podocalyxin-like 1 has been found to be expressed in several
CRC cell lines (Ito et al, 2007), but we are not aware of any
previous publication describing the prognostic impact of PODXL
expression in human CRC. In this study, we examined the
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(TMAs) representing tumours from 536 incident cases of CRC in
the prospective, population-based cohort Malmo ¨ Diet and Cancer
Study. The results demonstrate that PODXL expression is
associated with unfavourable clinicopathological characteristics
and an independent predictor of poor prognosis.
MATERIALS AND METHODS
The Malmo ¨ Diet and Cancer Study
The Malmo ¨ Diet and Cancer Study (MDCS) is an ongoing
population-based prospective cohort study with the primary aim
to examine whether a Western diet rich in fat and low in fruit and
vegetables increases the risk of certain forms of cancer (Berglund
et al, 1993). Between 1991 and 1996, a total number of 28098
individuals, 11063 (39.4%) men and 17035 (60.6%) women
between 44 and 74 years where enrolled (from a background
population of 74138). Follow-up is done annually by record
linkage to national registries for cancer and cause of death.
Approval for the MDCS (Ref. 51/90) and the present study (Ref.
530/2008) were obtained from the Ethics Committee at Lund
University.
Incident cases of CRC until 31 December 2008
Until the end of follow-up 31 December 2008, 626 incident cases of
CRC had been registered in the study population. Cases were
identified from the Swedish Cancer Registry up until 31 December
2007, and from The Southern Swedish Regional Tumour Registry
for the period of 1 January to 31 December 2008. All tumours with
available slides and/or paraffin blocks were histopathologically
re-evaluated on haemotoxylin and eosin-stained slides. Histo-
pathological, clinical and treatment data were obtained from
clinical and/or pathology records. TNM staging was performed
according to the American Joint Committee on Cancer (AJCC).
Information on vital status and cause of death were obtained
from the Swedish Cause of Death Registry up until 31 December
2009. Follow-up started at the date of diagnosis and ended at death,
emigration or 31 December 2009, whichever came first. Patient and
tumour characteristics are summarised in Supplementary Table 1.
TMA construction
Tumours with an insufficient amount of material were excluded,
and a total number of 557 (89%) tumours were suitable for
TMA construction. Areas representative of cancer were then
marked on haematoxylin and eosin-stained slides and TMAs were
constructed as previously described (Kononen et al, 1998). In
brief, two 1.0mm cores were taken from each tumour and
mounted in a new recipient block using a semi-automated arraying
device (TMArrayer, Pathology Devices, Westminster, MD, USA).
Immunohistochemistry and antibody validation
For immunohistochemical analysis, 4mm TMA sections were
automatically pre-treated using the PT-link system (DAKO,
Glostrup, Denmark) and then stained in an Autostainer Plus
(DAKO) with the affinity-purified polyclonal anti-PODXL antibody
HPA 2110 (Atlas Antibodies, Stockholm, Sweden, diluted 1:250).
The Envision Flex/HRP (K8010) kit (DAKO) was used for
visualisation of the staining. The specificity of this antibody,
originally generated within the Human Protein Atlas (HPA)
project, has been validated using western blotting and protein
arrays and PODXL protein expression has been mapped by
immunohistochemistry in 48 types of normal tissues and 20
common cancers (Uhlen et al, 2005; Ponten et al, 2008)
(www.proteinatlas.org). The same antibody has also been used to
detect PODXL expression in testicular carcinoma in a recent study
(Cheung et al, 2011).
To control for heterogenous expression patterns, IHC was also
performed on full-face sections from 10 randomly selected cases
denoted as having negative PODXL expression and 10 cases with
high (score 3–4) PODXL expression.
Evaluation of PODXL staining
Podocalyxin-like 1 was expressed in the cytoplasm of the tumour
cells, with an accentuation towards the membrane in some cases.
No expression was seen in the nuclei. The expression was recorded
as negative (0), weakly positive in any proportion of cells (1),
moderately positive in any proportion (2), positive with distinct
membranous pattern in p50% of cells (3) and positive with
distinct membranous pattern in 4 50% of cells (4). The staining
was evaluated by two independent observers (AL and KJ) who were
blinded to clinical and outcome data. Scoring differences were
discussed in order to reach consensus.
Statistical analysis
For statistical purposes, categories of PODXL expression were
trichotomised into negative (0), weak-moderate (1–2) and strong
(3–4) PODXL staining or dichotomised into low (0–2) and high
(3–4). Spearman’s Rho and w
2-tests were used for comparison of
PODXL expression and relevant clinicopathological characteristics.
Kaplan–Meier analysis and log rank test were used to illustrate
differences in cancer specific survival (CSS) and overall survival
(OS) according to PODXL expression. Cox regression proportional
hazards models were used for estimation of hazard ratios (HRs)
for death from CRC and overall causes according to PODXL
expression in both uni- and multivariate analysis, adjusted for age,
gender, TNM status, differentiation grade and vascular invasion. A
backward conditional selection method was used for variable
selection by the model. The interaction between PODXL expres-
sion and adjuvant chemotherapy was explored by a Cox model
including a treatment variable and an interaction variable. All tests
were two-sided. A P-value o0.05 was considered significant. All
statistical analyses were performed using SPSS version 18 (SPSS
Inc., Chicago, IL, USA).
REMARK criteria
A description of the fulfilment of REMARK criteria (McShane et al,
2005) for biomarker studies is provided in Supplementary Table 2.
RESULTS
PODXL expression in CRC
Following antibody optimisation and staining, PODXL expression
could be evaluated in 536 of the 557 (96.2%) of the tumours
represented in the TMA. A total of 268 tumours (50.0%) were
negative for PODXL, 196 (36.6%) displayed weak-moderate
staining and 72 (13.4%) strong staining for PODXL. As endothelial
cells express PODXL, entrapped vessels served as internal positive
control. Representative IHC images are shown in Figure 1 A–F.
Notably, in the majority of cases denoted as positive, PODXL was
distinctly expressed in scattered invasive cells at the tumour front,
corresponding morphologically with tumour budding (Prall, 2007)
(Figure 1D and E). Only one tumour (0.2%) had a strong, distinct
positive staining in 450% of tumour cells, as visualised
in Figure 1F. Podocalyxin-like 1 expression in full-face sections
(n¼20) correlated with the TMA-based scoring in all cases,
including the tumour in Figure 1F, further supporting the selective
distribution of PODXL-expressing cells in the majority of positive
tumours.
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clinicopathological characteristics
Analysis of the relationship between PODXL expression and
established clinicopathological parameters revealed a strong
correlation between high PODXL expression and more advanced
T-stage (Po0.001), N-stage (Po0.001), M-stage (P¼0.009), low
differentiation grade (Po0.001) and presence of vascular invasion
(P¼0.008) (Table 1). There was no significant association between
PODXL expression and age at diagnosis, gender or tumour
location (Table 1).
Association between PODXL expression and survival
Kaplan–Meier analysis revealed that PODXL expression correlated
with a significantly shorter CSS and OS, with the worst outcome for
tumours with high PODXL expression (Figure 2). These findings
were confirmed in univariate Cox regression analysis using a
dichotomised variable of low (0–2) and high (3–4) PODXL
expression (HR¼1.98; 95% confidence interval (CI) 1.38–2.84,
Po0.001 for CSS and HR¼1.85; 95% CI 1.29–2.64, P¼0.001 for
5-year OS), and remained significant for 5-year OS in multivariate
analysis (HR¼1.52; 95% CI 1.03–2.25, Po0.036) and borderline
significant for CSS (HR¼1.57; 95% CI 0.99–2.18, P¼0.055),
adjusted for age, gender, TNM status, differentiation grade and
vascular invasion (Table 2). Podocalyxin-like 1 expression was also
significantly associated with long-term OS, both in univariate
analysis (HR¼1.97; 95% CI 1.41–2.74, Po0.001) and multivariate
analysis (HR¼1.57; 95% CI 1.10–2.25, P¼0.014).
Impact of PODXL expression on survival in relation to
adjuvant chemotherapy
The impact of PODXL expression on survival in relation to
adjuvant treatment was analysed in 122 curatively resected stage
III (T1–4, N1–2, M0) patients, of whom 62 (50.8%) had received
adjuvant treatment and 60 (49.2%) had not. Kaplan–Meier
analysis in strata according to treatment and PODXL expression
demonstrated that patients having tumours with high PODXL
expression who were treated with adjuvant chemotherapy had a
similar CSS (Figure 3A) and OS (Figure 3B) as patients with low
PODXL-expressing tumours. Untreated patients with tumours with
high PODXL expression, however, had a significantly shorter CSS
and OS (Figure 3A and B). Cox interaction analysis (Table 3)
demonstrated that the P-value for the unadjusted interaction
variable between treatment and PODXL status was 0.044 for 5-year
OS, suggesting that patients having tumours with high expression
of PODXL had benefited from adjuvant chemotherapy, whereas
patients with low PODXL-expressing tumours did not benefit from
adjuvant treatment. In addition, when adjusted for established
prognostic factors, the term of interaction was significant for both
CSS (P¼0.004) and 5-year OS (P¼0.015) (Table 3). The treatment
benefit was similar for 5-fluorouracil alone or in combination with
oxaliplatin (data not shown).
In patients with stage II disease (n¼205), high PODXL
expression was associated with a significantly shorter OS
(HR¼3.03; 95% CI 1.45–6.34, P¼0.003) and 5-year OS
(HR¼2.83; 95% CI 1.14–7.16, P¼0.025), whereas the association
with CSS did not reach significance (HR¼2.19; 95% CI 0.84–5.75,
P¼0.11). Information on adjuvant chemotherapy was available for
170 patients with stage II disease, of whom only 13 (6.2%) had
received treatment, an insufficient number to allow for analysis of
a potential treatment benefit related to PODXL status in this group.
DISCUSSION
Our results demonstrate that overexpression of PODXL in CRC is
associated with unfavourable clinicopathological characteristics
and an independent factor of poor prognosis. This is to our
knowledge the first report on the prognostic value of PODXL
expression in human CRC and the results are based on a large
number of patients (n¼536) from a prospective cohort study.
In our study, 13% of the tumours were denoted as having
high expression of PODXL. In a previous study on breast cancer,
using a somewhat different cutoff, high expression of PODXL was
found in 6% of the tumours (Somasiri et al, 2004). These data,
together with the results from the antibody-based screening in
the Human Protein Atlas, demonstrate that, in most cancer types,
while upregulated compared with the corresponding normal
tissue, PODXL is overexpressed in a relatively small proportion
of cases.
ABC
DEF
Figure 1 Immunohistochemical images of PODXL staining representing colorectal tumours with (A) negative, (B) weak, (C) moderate, and (D–F)
strong, membranous staining in a varying proportion of tumour cells. All images are captured at  20 magnification.
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defined as a distinct cytoplasmic/membranous staining pattern,
this was predominantly observed in a subset of scattered and
infiltrating cells at the invasive tumour front. These findings are
substantiated by previous studies demonstrating that overexpres-
sion of PODXL enhances migratory and invasive properties of
tumour cells (Casey et al, 2006; Nielsen et al, 2007). Notably, the
only patient in this study with a tumour displaying PODXL
expression in 450% of the cells had generalised disease and died
within a month of diagnosis, further supporting that PODXL
expression is associated with an invasive and metastatic cellular
phenotype in CRC in vivo. Moreover, the upregulation of PODXL
expression observed at the infiltrating edge of the tumour
corresponds well to the morphological term ‘tumour budding’,
which has been demonstrated to be of prognostic importance
(Hase et al, 1993; Prall, 2007), and biologically closely related to
EMT (Prall, 2007). Studies have demonstrated that cancer cells at
the invasive front of primary tumours can convert to a motile
mesenchymal phenotype (Yang and Weinberg, 2008) and these
cells are considered to be the cells with metastatic potential. Along
this line, a high expression of PODXL has been recorded in TGFb-
induced EMT (Meng et al, 2011) indicating that PODXL has an
integral role in cancer progression.
Moreover, studies have illustrated a link between EMT and the
gain of stem cell-like properties such as mobility, anti-apoptosis
circuitry and low level of differentiation, which are traits of great
value for a malignant tumour (Mani et al, 2008). The PODXL has
previously been suggested as a marker for embryonal carcinoma
stem cells and haematopoietic stem cells (Schopperle et al, 2003)
and found to be upregulated in tumour stem cells in glioblastoma
(He et al, 2010).
In the light of these results, the development of therapies
targeting PODXL has been proposed as a new treatment strategy
(Chen et al, 2004; Somasiri et al, 2004). Our results, however,
Table 1 Association between PODXL expression and clinicopatho-
logical parameters
PODXL expression
n (%)
Negative
268 (50.0)
Weak-moderate
196 (36.6)
Strong
72 (13.4) P-value
Age
p75 186 (69.4) 137 (69.9) 45 (62.5) 0.484
475 82 (30.6) 59 (30.1) 27 (37.5)
Gender
Female 131 (48.9) 110 (56.1) 38 (52.8) 0.209
Male 137 (51.1) 86 (43.9) 34 (47.2)
T-stage
a
1 32 (12.5) 13 (6.8) 1 (1.4) o0.001**
2 36 (14.1) 21 (11.0) 7 (10.0)
3 157 (61.6) 130 (68.1) 40 (57.1)
4 30 (11.8) 27 (14.1) 22 (31.4)
Missing 13 5 2
N-stage
a
0 157 (64.6) 103 (56.9) 26 (37.7) o0.001**
1 53 (21.8) 48 (26.5) 21 (30.4)
2 33 (13.6) 30 (16.6) 22 (31.9)
Missing 25 15 3
M-stage
a
0 228 (86.4) 157 (80.9) 52 (73.2) 0.009**
1 36 (13.6) 37 (19.1) 19 (26.8)
Missing 4 2 1
Differentiation grade
High 21 (8.0) 12 (6.3) 1 (1.4) o0.001**
Intermediate 202 (76.8) 140 (72.9) 31 (43.7)
Low 40 (15.2) 40 (20.8) 39 (54.9)
Missing 5 4 1
Vascular invasion
No 85 (55.2) 52 (45.6) 15 (33.3) 0.008**
Yes 69 (44.8) 62 (54.4) 30 (66.7)
Missing 114 82 27
Location
Colon 160 (59.9) 117 (60.0) 49 (68.1) 0.300
Rectum 98 (36.7) 74 (37.9) 23 (31.9)
Multiple 9 (3.4) 4 (2.1) 0 (0)
Missing 1 1 0
**Significant at the 0.01 level.
aTNM staging was performed according to the AJCC
classification system: T1¼tumor invades submucosa; T2¼tumor invades muscularis
propria; T3¼tumor invades through the muscularis propria into the subserosa or
into non-peritonealized pericolonic or perirectal tissues; T4¼tumor penetrates the
visceral peritoneum or directly invades or is adherent to other organs or structures;
No¼no regional lymph node metastasis; N1¼metastasis in 1 to 3 regional lymph
nodes; N2¼metastasis in four or more regional lymph nodes; M0¼no distant
metastasis; M1¼distant metastasis.
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Figure 2 High expression of PODXL is associated with a poor outcome
in colorectal cancer patients. Kaplan–Meier analysis of (A) colorectal
cancer-specific survival and (B) overall survival according to PODXL
expression.
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also respond well to standard chemotherapy. Adjuvant chemo-
therapy reduces the risk of relapse but it also has side effects and
can be difficult to tolerate, especially for older patients. In CRC
Stage III, the recurrence-free survival increases with 10–20% by
adding adjuvant chemotherapy and in stage II the incremental gain
is only around 5%. Thus, only a minority of patients receiving
adjuvant chemotherapy have any benefit from it. Therefore, it
would be of great clinical value to find predictive tools for a better
selection of patients to such treatment.
The present study indicates that PODXL might be used as a
predictive marker for adjuvant treatment of CRC. In stage III,
patients with high tumour PODXL expression were the ones who
benefited from adjuvant chemotherapy, whereas patients having
tumours with low PODXL expression did not seem to have any effect
from the treatment. Whether the same is true in stage II could not be
determined in our study, as the number of stage II patients that
received adjuvant chemotherapy was too low for statistical analyses.
Even though the positive impact of chemotherapy in the
tumours with high PODXL expression remained significant in
multivariate analysis after correction for other prognostic factors,
our findings must be interpreted with caution as this was an
observational cohort study in which a potential selection bias
compared with the general population must be taken into
consideration (Berglund et al, 1993). The distribution of clinical
stages at diagnosis was, however, in line with the expected.
It is notable that only Bhalf of the patients with stage III
tumours in our study received adjuvant treatment, which is on the
low side compared with modern therapeutic guidelines. The main
reason for this is most likely that this study started already in the
mid 90s, during which time adjuvant chemotherapy was not yet
standard of care in Sweden.
In this study, CRC-specific survival and OS were used as
endpoints as this information had been recorded prospectively and
therefore was available for all patients. In future studies, the
impact of PODXL expression on recurrence free survival should
also be assessed, preferably in cohorts where this information has
been recorded prospectively. It will also be of value to correlate
PODXL expression to other relevant molecular characteristics of
CRC, for example, microsatellite instability status, KRAS, BRAF
and PIK3C mutations.
In summary, the results from this large cohort study suggest that
PODXL expression is independently associated with a poor
prognosis in CRC. Our findings also suggest that adjuvant
chemotherapy should be given to patients with tumours expressing
high levels of PODXL, whereas patients with low PODXL-
expressing tumours could be spared such treatment. Future
prospective studies are needed to confirm this association as well
Table 2 Cox uni- and multivariate analysis of relative risks of death from colorectal cancer and overall causes within 5 years according to PODXL
expression
Colorectal cancer-specific survival 5-year overall survival
HR (95% CI) P-value n (events) HR (95% CI) P-value n (events)
Univariate
PODXL low 1.00 464 (147) 1.00 464 (153)
PODXL high 1.98 (1.38–2.84) o0.001 72 (37) 1.85 (1.29–2.64) 0.001 72 (37)
Multivariate
PODXL low 1.00 417 (126) 1.00 417 (126)
PODXL high 1.57 (0.99–2.18) 0.06 68 (34) 1.52 (1.03–2.25) 0.036 68 (34)
Abbreviations: CI¼confidence interval; HR¼hazard ratio. Multivariate analysis included adjustment for age (4/p75 years), gender, T-stage (I–II, III, IV), N-stage (0, 1, 2),
M-stage (0, 1) differentiation grade (high-intermediate vs low) and vascular invasion (absent, present, missing).
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Figure 3 Kaplan–Meier estimates of (A) colorectal cancer-specific and
(B) overall survival according to combinations of PODXL expression (high
or low) and adjuvant chemotherapy (CT). Log rank P-values correspond to
pairwise comparisons of PODXL high and untreated tumours with the
other strata. Log rank P-values for overall survival (B) are given both for
5-year survival (in parentheses) and long-term survival.
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tumour behaviour.
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